Gevokizumab With Standard of Care Anti-cancer Therapies for Metastatic Colorectal, Gastroesophageal, and Renal Cancers
Completed · Phase 1
Conditions studied: Colorectal Cancer, Gastroesophageal Cancer, Renal Cell Carcinoma
In brief
This study will determine the pharmacodynamically-active dose of gevokizumab and the tolerable dose of gevokizumab in combination with the standard of care anti-cancer therapy in patients with metastatic colorectal cancer, metastatic gastroesophageal cancer and metastatic renal cell carcinoma, and the preliminary efficacy of gevokizumab in combination with the SOC anti-cancer therapy in subjects with mCRC and mGEC.
Key facts
- Study ID
- NCT03798626
- Run by
- Novartis Pharmaceuticals
- People needed
- 167
- Starts
- 2019-05-22
- Expected to finish
- 2025-02-05
- Last updated by the study team
- 2026-04-01
Who can join
Age: 18 and older, up to 100. Sex: any. Healthy volunteers: not accepted.
Where it is running
- University of California LA — Los Angeles, California, United States
- WA Uni School Of Med — St Louis, Missouri, United States
- Sarah Cannon Research Institute — Nashville, Tennessee, United States
- Novartis Investigative Site — Melbourne, Victoria, Australia
- Novartis Investigative Site — Brussels, Belgium
- Novartis Investigative Site — Edegem, Belgium
- Novartis Investigative Site — Leuven, Belgium
- Novartis Investigative Site — Calgary, Alberta, Canada
- Novartis Investigative Site — Toronto, Ontario, Canada
- Novartis Investigative Site — Santiago, Santiago Metropolitan, Chile
- Novartis Investigative Site — Brno, Czechia
- Novartis Investigative Site — Frankfurt am Main, Hesse, Germany
- Novartis Investigative Site — Dresden, Saxony, Germany
- Novartis Investigative Site — Ulm, Germany
- Novartis Investigative Site — Ramat Gan, Israel
- Novartis Investigative Site — Tel Aviv, Israel
- Novartis Investigative Site — Milan, MI, Italy
- Novartis Investigative Site — Rozzano, MI, Italy
- Novartis Investigative Site — Nagoya, Aichi-ken, Japan
- Novartis Investigative Site — Kashiwa, Chiba, Japan
- Novartis Investigative Site — Osaka, Osaka, Japan
- Novartis Investigative Site — Sunto Gun, Shizuoka, Japan
- Novartis Investigative Site — Bunkyo-ku, Tokyo, Japan
- Novartis Investigative Site — Singapore, Singapore
- Novartis Investigative Site — Seoul, South Korea
Full record on ClinicalTrials.gov
Trial information comes from ClinicalTrials.gov and is refreshed daily. TrialsForMe does not provide medical care and does not run the studies it lists.